GSK4172239
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 30, 2025
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Nov 2025 ➔ Feb 2026 | Trial primary completion date: Nov 2025 ➔ Feb 2026
Trial completion date • Trial primary completion date • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
October 10, 2024
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2025
Trial completion date • Trial primary completion date • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
September 08, 2023
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2023 ➔ Aug 2023
Enrollment open • Trial initiation date • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
December 21, 2022
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P1 trial • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
1 to 4
Of
4
Go to page
1